GUIDELINE for Vaccination of Immunocompromised Cats

Published: 01/08/2020
Last updated: 09/06/2022
Last reviewed: 05/06/2023

These guidelines were drafted by Katrin Hartmann et al. in May 2017 and published in *Viruses* 14 (2022), 923. This update was compiled by Katrin Hartmann.

Introduction

This guideline has the goal to help veterinarians in the decision making in how to vaccinate immunocompromised cats. So far, there are not much data available on vaccination of immunocompromised cats, and sometimes studies produce controversial results. Thus, this guideline is mainly based upon expert opinion, wherever scientific studies are missing.

In this guideline, the terms immunocompromised and immunocompromise are generally used and are considered alternative terms for immunosuppressed and immunosuppression as well as immunodeficient and immunodeficiency. Immunocompromise is a reduction of the activation or efficacy of the immune system. An animal or person who is undergoing immunosuppression or whose immune system is weak for other reasons is classified as to be immunocompromised or having an immunocompromised condition. An immunosuppressant is any agent that weakens the immune system, including infectious agents, immunosuppressive drugs, and toxins. Immunodeficiency (or immune deficiency) is the state resulting from immunocompromise in which the immune system's ability to combat infectious diseases and tumours is compromised or completely absent.

Vaccination of immunocompromised individuals is an important issue, not only in human medicine, but also in veterinary medicine, and especially in cats. There are a number of immunocompromising conditions in cats, due to common infectious diseases with immunosuppressive viruses, such as feline immunodeficiency virus (FIV) and feline leukaemia virus (FeLV), and to chronic non-infectious immunocompromising diseases, such as tumours, diabetes mellitus, and chronic kidney disease, as well as treatment with immunosuppressive drugs, such as glucocorticoids, cyclosporins, or tumour chemotherapy.

Life expectancy in cats has been increasing in recent decades, especially in privately owned cats receiving good preventive, medical and nutritional care. Simultaneously, the prevalence of chronic diseases increases in older animals. Now, senior cats represent a large percentage of patients in practice; this tendency will probably even further increase in the future. In human medicine, specific recommendations exist on vaccination of immunocompromised people, such as the "Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of Vaccines and Immune Globulins in Persons with Altered Immunocompetence of the Centers for Disease Control and Prevention (Centers for Disease Control and Prevention, 1993) or the Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for Vaccination of the Immunocompromised Host (Rubin et al., 2014) as well as several review articles (Ljungman, 2012; Jablonka et al., 2019; Goorhuis et al., 2020). In addition, comprehensive systematic reviews and meta-analyses on specific vaccinations, such as against influenza in immunocompromised people have been published (Atashili et al., 2006; Anema et al., 2008; Beck et al., 2012), and since vaccines against SARS-CoV-2 have become available, recommendations also exist for COVID-19 vaccination in immunocompromised people (Luxi et al., 2021; Negahdaripour et al., 2021; Sonani et al., 2021). Data in cats are limited and not many controlled studies in immunocompromised animals have been conducted. Thus, most of the following recommendations are based on data obtained either in humans or in dogs, as well as on expert opinions.

The degree to which an individual cat is immunocompromised should be determined by the veterinarian. Severe immunocompromise can be due to a variety of conditions, including congenital immunodeficiency, FIV or FeLV infection, tumours, tumour chemotherapy or radiation, glucocorticoids, cyclosporins, or other immunosuppressive drugs. For some of these conditions, the affected cats will be severely immunocompromised; for others, such as FIV infection, the spectrum of different infection stages will determine the degree to which the immune system is compromised. As a general recommendation, cats with acute diseases or undergoing short-term immunosuppressive treatment should not be vaccinated, and vaccination should be postponed until recovery or after termination of the

treatment course. However, in some situations, postponing of vaccination would pose a significant risk for the cat, such as when entering a shelter environment with high infectious pressure. In these specific situations vaccination might be necessary despite acute illness or poor general condition. For sick cats, any decision about vaccination has to be taken for the individual cat, but when entering a shelter, vaccination is recommended whenever and as soon as justifiable (ABCD, 2021b). In acutely ill cats when immediate protection (against other infectious diseases) is required, passive immunisation should be used instead of active immunisation (e.g., with serum containing antibodies against feline panleukopenia virus (FPV), feline herpesvirus (FHV), and feline calicivirus (FCV), as a commercial compound or as hyperimmune serum obtained from another cat).

Some cats are immunocompromised long-term, and this guideline will concentrate on these conditions. Some important points must be considered when vaccinating immunocompromised cats, including

(1) the safety of modified-live virus vaccines and the concern that the infectious agent in certain vaccines might regain their pathogenicity if the immune system is not working properly,

(2) the question whether vaccines work at all in immunocompromised cats and whether duration of immunity after vaccination is shortened compared to that in healthy cats,

(3) the concern that in some of these conditions, e.g., in cats with FIV infection or chronic kidney disease, vaccination and resulting immunostimulation might lead to a progression of the disease.

Table 1. Vaccination recommendations in immunocompromised cats

Tab. 1. Vaccination recommendations in cats with immunocompromise

CONDITION OR SITUATION THAT COULD BE ASSOCIATED WITH IMMUNOCOMPROMISE	MEASURE FPV ANTIBODIES*	RECOMMENDED VACCINATION PROTOCOL
Acute disease or short-term immunosuppressive treatment	No**	(1); alternatively: (2)
Congenital immunodeficiency disorders	Yes	(3)
Feline immunodeficiency virus (FIV) infection	Yes	(5); (6); (7)
Feline leukaemia virus (FeLV) infection	Yes	(5); (6); (8)
Tumours	Yes	If otherwise healthy and no current chemotherapy: (3)
Diabetes mellitus	Yes	If well controlled: (3); If poorly controlled: (1) until improvement; alternatively: (2)
Chronic kidney disease	Yes	(7)
Asplenia	Yes	(3); In case of elective splenectomy: (9)
Long-term glucocorticoid therapy	Yes	If cat is on low-dose anti-inflammatory glucocorticoid treatment: (3); If cat is on high-dose or long-term immunosuppressive glucocorticoid treatment: (4); alternatively: (2)
Long-term cyclosporine therapy	Yes	Primary vaccination series: (4); alternatively: (2); Booster vaccination (if cat otherwise healthy): (3)
Chemotherapy for tumours	Yes	(4); alternatively: (2)

CONDITION OR SITUATION THAT COULD BE ASSOCIATED WITH IMMUNOCOMPROMISE	MEASURE FPV ANTIBODIES*	RECOMMENDED VACCINATION PROTOCOL
General anaesthesia / peri-operative period	Potentially***	(1); if vaccination cannot be avoided (e.g. trap-neuter): (3)
Senior cats (>11 years)	Yes	Primary vaccination series: (10) Booster vaccination: (3)

* To avoid unnecessary vaccination against feline panleukopenia virus (FPV) in case antibody levels are adequate

** Vaccination should be avoided even if no antibodies are present; therefore measuring FPV antibodies is not useful in this situation.

*** Depending on the situation, antibody measurement might be useful in adult cats that have to be vaccinated in this situation to avoid unnecessary vaccinations

Notes for table

(1) Postpone vaccination until recovered/end of treatment.

(2) Consider administering passive immunisation (transfer of antibodies against FPV, feline calicivirus (FCV), and feline herpesvirus (FHV)) if available in case of high infectious pressure.

(3) Vaccinate as for clinically healthy cats.

(4) Postpone vaccination until at least 3 months after the end of treatment.

(5) Keep retrovirus-infected cats strictly indoors.

(6) Only consider vaccination if the cat is clinically healthy.

(7) Base decision to vaccinate on risk-benefit ratio, e.g. avoid vaccinating indoor-only adult cats (unless the cat lacks FPV antibodies).

(8) Consider annual booster of core vaccines.

(9) Complete vaccination at least 2 weeks before surgery.

(10) Give 2 injections of primary vaccination series at a 3-to-4-week interval (including MLV and rabies vaccines) OR perform FPV and rabies antibody measurement after the first injection to verify if protection is adequate.

Cats with Congenital Immunodeficiency Disorders

Congenital (primary) immunodeficiency in cats has rarely been described (Kraft, 1996; Datz, 2010; DeBey, 2010). In human medicine, it is recommended that patients with primary immunodeficiency should receive all routine vaccines based on the Center of Disease Control annual schedule. None of the vaccines are contraindicated (Rubin et al., 2014). Due to lack of data in cats, this recommendation should be followed in cats with congenital immunodeficiency as well.

In conclusion, for **cats with congenital immunodeficiency disorders** no data are available; they should be vaccinated as clinically healthy cats.

Cats with Retrovirus Infections

In domestic cats, three retroviruses have been identified: FIV, FeLV, and feline foamy virus (FeFV). All three are global and widespread, but differ in their potential to cause disease (Hartmann, 2014). FeFV (previously known as feline syncytium-forming virus, FeSFV), a spumavirus, is not associated with disease (Cavalcante et al., 2018), and no special management is required in cats with FeSFV infection. FIV, a lentivirus that shares many properties with human immunodeficiency virus (HIV), can cause an acquired immunodeficiency syndrome in cats leading to increased risk for opportunistic infections, neurologic diseases, and tumours. In the majority of naturally infected cats, FIV infection does not cause severe clinical syndromes, and with proper care FIV-infected cats can live for many years (Hosie et al., 2009; Beczkowski et al., 2015; Spada et al., 2018). FeLV, an oncornavirus, is the most pathogenic of the three viruses. Even though progressive FeLV infection is associated with a decrease in life expectancy, many FeLV-infected cats kept solely indoors will live for many years with good quality of life (ABCD, 2018). Cats with FIV or FeLV infection can have long asymptomatic stages with no or only little immunocompromise, but in a later stage can become severely immunocompromised.

Cats with feline immunodeficiency virus (FIV) infection

FIV infection leads to progressive disruption of normal immune function (Sellon and Hartmann, 2006; Hosie et al., 2009). Early and persistent immunologic abnormalities that occur after experimental (Ackley et al., 1990; Barlough et al., 1993) and natural (Novotney et al., 1990; Hoffmann-Fezer et al., 1992) infection include decreases in both the number and relative proportions of CD4+ T cells in the peripheral blood as well as in lymphoid tissues. Ultimately, loss of CD4+ T cells impairs immune responses because CD4+ T cells play critical roles in promoting and maintaining both humoral and cell-mediated immunity. Over time, lymphocytes lose the ability to proliferate in response to stimulation with lymphocyte mitogens or recall antigens, and have impaired priming by immunogens in vitro (Hosie and Jarrett, 1990; Taniguchi et al., 1990; Barlough et al., 1991; Taniguchi et al., 1991; Bishop et al., 1992a; Bishop et al., 1992b; Hanlon et al., 1993). Lymphocyte function can also be impaired by reduced or altered expression of cell surface molecules, such as CD4+, major histocompatibility complex antigens or other co-stimulatory molecules, cytokines and cytokine receptors (Willet et al., 1991; Ohno et al., 1992; Rideout et al., 1992), or even the expression of abnormal molecules (Nishimura et al., 2004). Many of these molecules have a critical role in antigen presentation or amplification and control of immune responses.

It has been proposed that cats with FIV infection should solely receive inactivated vaccines, if possible, out of the concern that the virus components of modified-live virus vaccines given to immunocompromised animals might regain pathogenicity (Krakowka et al., 1982; Meyer, 2001; Dodds, 2002). However, there is no definitive scientific proof that FIV-infected cats are at increased risk from modified-live virus vaccines (ABCD, 2017). The use of "old" modified-live virus vaccine against canine distemper virus (CDV) in dogs experimentally infected with canine parvovirus (CPV) resulted in development of encephalomyelitis, which was presumably due to an immunosuppressive effect of CPV infection. It has been reported that FIV-infected cats have developed illness after being vaccinated with modified-live panleukopenia vaccine (Greene and Levy, 2012).

However, in a pilot study comparing reaction to vaccination of four asymptomatic FIV-infected cats after modified-live panleukopenia vaccination to that of uninfected healthy cats in the field, no vaccine-associated adverse events (VAAEs) were noted (Bergmann et al., 2019).

The efficacy of vaccination seems to depend on the stage of FIV infection. It has been shown that FIV-infected cats in an early stage of infection are able to mount appropriate levels of protective antibodies after vaccination (Lawrence et al., 1995; Bergmann et al., 2019), but responses can be impaired during the terminal phase of infection (Foley et al., 2003). One pilot study compared the immune response of four asymptomatic FIV-infected cats within a period of 28 days after modified-live virus vaccination against FPV to that of not-infected healthy cats in the field; there were no differences in antibody levels between the two groups and none of the FIV-infected cats developed illness or VAAEs (Bergmann et al., 2019). In another study, 15 cats experimentally infected with FIV and 15 FIV-negative control cats received a FeLV vaccine. High anti-FeLV-antibody titres developed after vaccination in both FIV-infected and FIV-negative cats. After challenge with FeLV, FIV-infected cats were protected as well as the non-FIV-infected cats. Thus, in this study at least in the early stage of FIV infection, the immune system was not markedly compromised, and therefore, cats could be successfully immunized (Lehmann et al., 1991). In a follow-up experimental study, long-term protection of a FeLV vaccine in FIV-infected cats was determined following 30 cats for over three years. Half of the cats had previously been infected with FIV; the other 15 cats served as non-infected controls. There was no difference in the efficacy of the FeLV vaccine between FIV-infected and FIV-negative cats. After three years of observation, the FeLV-vaccinated FIV-infected cats had significantly higher survival rates as well as better clinical and laboratory parameters than the not-FeLV-vaccinated FIV-infected cats, thus indicating, that the FeLV vaccine was effective in these FIV-infected cats (Hofmann-Lehmann et al., 1995). In contrast, in one study investigating the effect of experimental primary-stage FIV infection on feline calicivirus (FCV) vaccination and subsequent challenge, there was a difference between FIV-infected and non-infected cats. Although there was some level of protection through vaccination, clinical signs of acute FCV-associated disease were more widespread in the cats infected with FIV than in those which were non-infected. FIV infection also prolonged the shedding of FCV, with more FIV-infected cats becoming chronic carriers. There was also evidence of an impaired anti-FCV-neutralizing antibody response in FIV-infected cats following FCV challenge (Dawson et al., 1991). In addition, in a five-year field trial aimed to control FeLV infection by vaccination in a colony of 30 adult cats naturally exposed to FeLV, FeLV vaccination was effective in FIV-uninfected cats, but failed to protect FIV-infected cats against FeLV (Bandecchi et al., 2006). Obviously, there are major differences in the response to vaccination depending on the immune status of the individual FIV-infected cat.

In addition to concerns about efficacy, there is debate about negative effects of vaccine-induced immunostimulation in FIV-infected cats, as immunostimulation could potentially lead to progression of FIV infection by altering the balance between the immune system and the virus (Sellon and Hartmann, 2006). Although some studies even suggest that immunostimulation can help to stabilize CD4+ cell numbers (Reubel et al., 1994), vaccination of chronically infected FIV-infected cats with a synthetic peptide on the other hand was associated with a decrease in the CD4+/CD8+ ratio (Lehmann et al., 1992). Stimulation of FIV-infected lymphocytes is known to promote FIV production *in vitro*, and *in vivo*, lymphocyte stimulation can increase the expression of cellular FIV receptors and increase virus production, a combination that could enhance progression of infection. Thus, vaccination and antigenic stimulation might potentially be disadvantageous.

In conclusion, if adult **FIV-infected cats** that had been vaccinated previously, are kept strictly indoors, the risk of being infected with other pathogens is likely lower than the possible harmful effect of vaccination. Ideally, antibody levels against FPV, should be determined (Mende et al., 2014b) and FPV vaccination should only be considered in cats lacking protective antibodies. If antibody measurement is not possible, booster vaccinations in adult indoor-only cats, that have received previous vaccinations in their lives, are not recommended. If potential exposure to FPV, FHV, or FCV cannot be excluded, only core vaccines should be administered, preferably in inactivated form.

Cats with feline leukaemia virus (FeLV) infection

Cats with progressive FeLV infection are more severely immunocompromised than those with FIV (Lutz et al., 2009; Hartmann, 2012; Hartmann, 2014; ABCD, 2018; Hartmann and Hofmann-Lehmann, 2020); they have suppressed cellular and humoral immunity, thus predisposing them for just about any type of infection. Therefore, maintaining a good level of protection is considered very important. While FIV preferentially replicates in CD4+ T cells and macrophages, FeLV can replicate and destroy virtually all haematopoietic cells. Lymphopenia and neutropenia are common in FeLV-infected cats. In some cats, lymphopenia is characterized by preferential loss of CD4+ helper T cells, resulting in an inverted CD4+/CD8+ ratio (comparable to FIV infection) (Quackenbush et al., 1990; Hoffmann-Fezer et al., 1996), but more commonly, substantial losses of both CD4$^+$ and CD8$^+$T cells occur (Hoffmann-Fezer et al., 1996). Many immune function tests of naturally FeLV-infected cats are abnormal, including poor response to T-cell mitogens, prolonged allograft reaction, reduced immunoglobulin production, depressed neutrophil function, complement depletion, and altered cytokine levels (Linenberger and Deng, 1999). Finally, primary and secondary humoral responses to specific antigens are delayed and decreased in FeLV-infected cats. Cats with FeLV-associated myelosuppression have a particularly strong immunosuppression because of the occurring pancytopenia (Hartmann, 2012).

Although it has been recommended that FeLV-infected cats should receive inactivated vaccines and not those containing modified-live virus (when available), there is little evidence that such cats are indeed at increased risk of VAAEs through those vaccines (Levy et al., 2008). One pilot study comparing the response to vaccination in four asymptomatic FeLV-infected cats after modified-live virus vaccination against FPV to that of non-infected healthy cats in the field did not detect any illness or VAAEs in any of the FeLV-infected cats (Bergmann et al., 2019).

It has been shown that cats with progressive FeLV infection might not adequately respond to vaccination. When cats with FeLV infection were vaccinated with rabies vaccines, they were only protected for six months (Franchini, 1990). This has been proven for rabies but might also be true for other vaccine components. In contrast, one pilot study that compared the immune response of four asymptomatic FeLV-infected cats after modified-live virus vaccination against FPV to that of non-infected healthy cats in the field, observed no differences in antibody levels between the two groups. However, in this study, evaluation of immune response was not performed beyond 28 days after vaccination (Bergmann et al., 2019).

In conclusion, for good protection of **FeLV-infected cats**, vaccination with core vaccines (against FPV, FHV, and FCV) should be performed regularly, even if the cat is kept strictly indoors (this is different to FIV-infected cats). If an owner cannot be convinced to keep a FeLV-positive cat inside, rabies vaccinations should be given (in accordance with state and local regulations). Protection in a FeLV-infected cat after vaccination might not be as complete and long-lasting as in a non-infected cat. Thus, either more frequent vaccinations (e.g., annualy) or measurement of antibody titres to ensure sufficient protection against FPV (Mende et al., 2014b) is recommended.

Cats with Tumours

Patients with neoplastic conditions can be immunocompromise for several reasons, including conditions caused by the tumour itself, e.g., debilitation, acquired disorders of antibody production and cell-mediated immunity, and the drugs used to treat the tumour (Muneer et al., 1988). Furthermore, active tumour growth is associated with profound protein loss, which can also impair the immune response (Dodds, 2002). Splenectomy performed to remove a splenic tumour can also compromise the patient (Schaer, 2008). Tumours can lead to immunosuppression that favours tumour progression and metastasis and evolves by constitution of an immunosuppressive network, which is mediated by several tumour-derived soluble factors, such as interleukin-10, transforming growth factor-b, and vascular endothelial growth factor, and which extends from the primary tumour site to secondary lymphoid organs and peripheral vessels (Kim et al., 2006). In this context, the tumour microenvironment is of importance (Spano and Zollo, 2012). Tumour-associated macrophages can be attracted by the production of chemokines from mesenchymal stromal/stem cells within the tumour (Day and Schultz, 2014a). Interactions between tumours and the immune system are very complex and further factors leading to immunocompromise are currently being discovered. For example, a specific suppression of the secretion of interferon-γ was detected in cultured splenocytes of mice with murine breast cancer mediated by a soluble protein (Kano, 2015).

The nature of immunocompromise can vary depending on the type of tumour. Some specific tumours, such as multiple myeloma and some lymphomas, can cause acquired disorders of antibody production. This is more likely to happen when the tumour cells produce a

paraprotein increasing globulin production but simultaneously interfering with the patient's normal antibody response (Schaer, 2008; Day and Schulz, 2014a; Tizard, 2018a). In cats with tumour-associated disorders of antibody production, vaccination is very unlikely to be effective. There are also neoplastic disorders that can cause neutropenia, which is amongst the most important risk factors for serious infection in the immunocompromised host. A severe neutropenia can be seen in myelophthisic disease caused by spread of the tumour to the bone marrow. Myelophthisis can occur with both lymphoma and carcinoma types of neoplasia (Schaer, 2008).

In humans, meta-analyses on efficacy of influenza vaccination in patients with tumours revealed a significantly reduced immunological response in patients with tumours compared to controls, although this was not the case in all studies. Adult human tumour patients had depressed antibody responses to immunisation even before starting chemotherapy (Lehane and Lane, 1974). On the other hand, no evidence of serious VAAEs or disease progression was identified as being related to the administration of influenza vaccine. Thus, recommendations in human medicine state that vaccination should be maintained in humans with tumours (Beck et al., 2012; Rubin et al., 2014), but no modified-live virus vaccines should be administered, because replication of the vaccine virus could be enhanced in severely immunocompromised persons (Mitus et al., 1962; Bellini et al., 1992).

A few studies in dogs demonstrated immunosuppression associated with various tumours, such as lymphoma (Weiden et al., 1974; Dutta et al., 1978; Calvert et al., 1982; Karayannopoulou et al., 2017). Dogs with lymphoma had reduced T cell numbers when compared to healthy dogs, and dogs with osteosarcoma also had reduced T and B cell numbers (Walter et al., 2006). One study demonstrated the immunosuppressive network in dogs with mammary carcinoma; while the number of various T cell subpopulations was constant during tumour development, the number of regulatory T cells was significantly higher in tumour-bearing dogs than in healthy individuals, as was the number of myeloid-derived suppressor cells (Mucha et al., 2016). This heterogeneous cell population in mostly immature developmental stages induces molecules and factors that are essential for tumour growth and neovascularization; however, they also have a potent inhibitory activity on tumour-specific as well as non-specific T cells and thus, contribute significantly to the dysfunction of the T cell-mediated immune response (Serafini et al., 2006). In one study, dogs with lymphoma or osteosarcoma were vaccinated, and post-vaccination antibody titres were compared to those of a healthy control group. Although dogs with lymphoma or osteosarcoma appeared to be relatively T cell-deficient, antibody titres after vaccination were not significantly different to those of healthy controls (Walter et al., 2006).

No studies have been performed in cats with tumours to demonstrate their ability to react to vaccination. However, one study assessed the prevalence of antibodies against FPV in 350 client-owned cats and identified factors that were associated with a lack of antibodies in cats. Factors, including information regarding signalment, origin, environment, lifestyle, housing conditions, health status, chronic diseases, glucocorticoid therapy, and vaccination status were analysed by a multivariable logistic regression analysis. Of the 350 cats, 103 (29.4%) had no antibodies against FPV, and among other factors, tumours were significantly associated with a lack of antibodies (Mende et al., 2014a). Thus, in cats with tumours, protection rate is not comparable to those of healthy cats.

In conclusion, in **cats with tumours**, antibody measurement against FPV infection is a good option to confirm that protection against panleukopenia is present. Vaccination can be considered in otherwise healthy cats with tumours not receiving chemotherapy. In those receiving chemotherapy, vaccination ideally should precede the initiation of chemotherapy by at least two weeks. If this is not possible, vaccination should be postponed until at least three months after the end of chemotherapy.

Cats with other Immunosuppressive Diseases

There are several other diseases that can alter the immune system, such as diabetes, chronic kidney disease, and asplenia. In humans, these conditions increase the patient's risk for certain diseases, and thus, specific vaccines, particularly bacterial vaccines, are recommended for such patients (National Center for Immunization and Respiratory Diseases, 2011; Rubin et al., 2014; Nieman et al., 2015). Frequently, the immune response of those patients to bacterial antigens is not as good as that of immunocompetent persons, and higher doses or more frequent boosters might be required. In humans, liver cirrhosis is also included in the guidelines as an important immunocompromising disease (Rubin et al., 2014); this is a very rare condition in cats and thus will not be further discussed in the present guideline.

Diabetes mellitus

Diabetes mellitus can alter the body's immune defences, therefore rendering the patient predisposed to infection. The reasons for this have not been completely explained but can involve abnormalities with cell-mediated immunity (Greco and Harpold, 1994) and abnormal phagocyte function (Robertson and Polk, 1974), as well as poor blood supply to various body tissues because of diabetic vascular disease (Schaer, 2008). Thus, infections in animals with diabetes are more common and severe and can involve the skin, urinary tract, and other body sites, such as the gall bladder and liver (Schaer, 2008). In diabetic cats, urinary tract infections are the most common secondary infections (Bailiff et al., 2006; Mayer-Roenne et al., 2007).

Although several in vitro tests of immunologic function are known to be abnormal among diabetic patients, these defects are likely of little clinical importance. In humans with longstanding diabetes, who often have cardiovascular, renal, and other end-organ

dysfunctions, vaccinations are recommended. In one study, patients receiving either insulin or oral antidiabetic medications responded normally to influenza vaccination without impairment of diabetic control (Feery et al., 1983). Also, pneumococcal vaccines were safe and effective in diabetic patients and did not interfere with insulin levels or glucose control (Beam et al., 1980; Lederman et al., 1981). In a study on vaccination of elderly people, patients with diabetes showed an immune response comparable to that of other non-diabetic participants (Govaert et al., 1994). Still, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention recommends to vaccinate adult diabetic patients as early as possible after their diagnosis (Centers for Disease Control and Prevention, 1993).

The immune function of a diabetic patient, however, is more severely compromised if the patient remains uncontrollably hyperglycaemic (Berbudi et al., 2020). Thus, vaccinations should never be given to a cat with poorly controlled diabetes, and control of the diabetic situation should be achieved before vaccination. In cats, infections play an important role in inducing insulin resistance and by causing diabetic decompensation because of endogenous hypersecretion of stress hormones, such as cortisol (Schaer, 2008). There are no data, however, as to whether vaccination could promote diabetic decompensation.

Thus, in conclusion, the recommendation would be to vaccinate **diabetic cats** according to the proposed guidelines for healthy cats, but postpone vaccination in an uncontrolled diabetic case until control is achieved. Antibody measurement against FPV infection would also be a good possibility to confirm that protection is present.

Chronic kidney disease

Patients with kidney disease have an increased risk of infection with a variety of pathogens (Linneman and First, 1979; Alter et al., 1986; Schwebke and Mujais, 1989; Johnson and Fleming, 1992). An association between chronic kidney disease and reduced antibody development following vaccination has been described in humans. The efficacy of pneumococcal vaccination for some of these patients, including those on dialysis, was considerably lower than for immunocompetent patients (Simberkoff et al., 1980; Cosio et al., 1981), their antibody levels might also be lower (Linneman et al., 1981). Therefore, they might require repeated vaccinations (Linneman et al., 1986; Rytel et al., 1986) or an increased number of vaccine doses. It has been shown that the stage of the kidney disease and thus, the impairment of the glomerular filtration rates predict ability to produce antibodies (DaRoza et al., 2003), since a rise of antibody titres after vaccination became increasingly unlikely as glomerular filtration rate decreased (DaRoza et al., 2003). Malnutrition in patients with chronic kidney disease was also suspected to be associated with an impaired immune response (Lombardi et al., 1992), and chronic uraemia, directly or indirectly, was shown to alter immune cell function (Pesanti, 2001). Consequently, a generalized immunosuppression and decreased antibody development are expected in chronic kidney disease patients with secondary antibody responses being less affected than primary antibody responses. Thus, immunisation strategies and especially vaccination with novel antigens should be given as early in the course of the chronic kidney disease as possible (Centers for Disease Control and Prevention, 1993).

No studies have been performed in cats with chronic kidney disease to demonstrate their ability to respond to vaccination. However, one study assessed the prevalence of antibodies against FPV in cats in Southern Germany and identified factors that were associated with a lack of antibodies in 350 client-owned cats, and the presence of chronic kidney disease was significantly associated with a lack of antibodies (Mende et al., 2014a). Thus, in cats with chronic kidney disease, protection rate is not comparable to those of healthy animals.

There is another concern that has to be discussed when considering vaccination in cats with chronic kidney disease. Some studies suggest a risk association between chronic kidney disease and frequent vaccination in cats (Finch et al., 2016; Brown et al., 2016). A risk factor analysis on the development of chronic kidney disease in cats evaluated clinical and questionnaire data to identify risk factors in 148 client-owned older cats (> 9 years) followed longitudinally for a variable time. Besides dental diseases, the only significant risk factor identified in the final multivariable Cox regression model was indeed annual/frequent vaccination, suggesting an association between vaccination frequency and development of chronic kidney disease (Finch et al., 2016). Such an association has already been proposed in earlier studies that were aimed at identifying antibodies against feline kidney cells in vaccinated cats. Vaccine viruses are usually grown on Crandell-Rees feline kidney (CRFK) cells, and it was hypothesized that vaccinated cats would produce antibodies against CRFK cells, that could interact with their own kidney tissues and thus, could be a trigger for interstitial nephritis. Parenteral administration of CRFK cell lysates or FPV, FHV, and FCV vaccines grown on CRFK cells induced antibodies in cats against CRFK cells. These antibodies also reacted with feline renal cell extracts. In contrast, control cats that had received an intranasal vaccine did not develop detectable antibodies against CRFK cells (Lappin et al., 2005). A follow-up study tested whether interstitial nephritis could be detected in cats that were immunologically sensitized with CRFK lysates, boosted with CRFK lysates, and then had kidney biopsy two weeks after the booster. Cats were immunologically sensitized against CRFK lysates twelve times in the first 50 weeks over two years. Half of the cats sensitized with CRFK lysates indeed developed lymphocyticplasmacytic interstitial nephritis (Lappin et al., 2006).

In another study, 44 kittens were inoculated with CRFK lysates and FPV, FHV, and FCV vaccines. Several CRFK antigens were identified

in the kittens, and protein isolation and sequencing identified them as alpha-enolase, annexin A2, and macrophage capping protein (MCP). Sera from vaccinated and CRFK-inoculated kittens confirmed to recognize annexin A2 and alpha-enolase by Western blot and indirect ELISA. In humans, alpha-enolase antibodies are nephritogenic; alpha-enolase and annexin A2 antibodies have been associated with autoimmune diseases (Whittemore at al., 2010), and it was shown that alpha-enolase decreases in damaged renal tubules and increases in the glomeruli of older cats prior to the development of detectable CKD (McLeland et al., 2019).

One study produced anti-cat kidney antibodies in rabbits (Songaksorn et al., 2019) to examine serum samples and kidneys collected from 156 live and 26 cats at necropsy to evaluate whether FHV, FCV, and FPV vaccines, prepared from viruses grown in CRFK cells, could induce antibodies to cross-react with feline kidney tissues. The prevalence of autoantibodies that bound to kidney tissues in cats were 41% and 13% by ELISA and immunofluorescence, respectively; there was no direct link between vaccination and anti-kidney antibodies, but the presence of antibodies to kidney tissues was significantly associated with anti-FHV/-FCV/-FPV antibodies (Songaksorn et al., 2021).

Although these studies suggest a possible association between vaccination and chronic kidney disease in cats, there is no causative proof and further studies are required.

In conclusion, however, as most of the **cats with chronic kidney disease** are of older age and are likely to have received vaccinations in the past, the risk for such a cat to acquire infectious diseases is considered low, and so vaccination might not be necessary in these cats. Ideally, antibody levels against FPV should be determined; only cats lacking protective antibodies should be vaccinated against panleukopenia. If antibody measurement is not possible, booster vaccination is not recommended for a cat with chronic kidney disease that has been vaccinated previously and is kept strictly indoors. If potential exposure to FPV, FHV, or FCV cannot be excluded, an intranasal vaccine should be given if available.

Asplenia

People who have anatomic or functional asplenia have an increased risk for infectious diseases, especially fulminant bacteraemia associated with high mortality. It has been shown that antibodies after pneumococcal vaccination decline almost linearly by 24 to 32% within the first year after splenectomy (Giebink et al., 1981). Thus, in human medicine, vaccines, especially against bacterial pathogens, such as pneumococcal and meningococcal vaccines, are considered important for all asplenic persons (Centers for Disease Control and Prevention, 1993).

Asplenia is rare in cats and mainly occurs after iatrogenic removal of the spleen. Asplenia is more common in dogs, and dogs without a spleen are at increased risk to develop clinical manifestations of bacterial or parasitic infections that are otherwise usually asymptomatic, such as infections with *Mycoplasma haemocanis* (Kemming et al., 2004; Hulme-Moir et al., 2010; Pitorri et al., 2012). In addition, novel bacterial or parasitic species have been detected in asplenic dogs, such as a new haemoplasma spp. *'Candidatus* Mycoplasma haematoparvum' (Sykes et al., 2005) or a new large *Babesia* spp. (Sikorski et al., 2010). In cats, studies on the outcome following laparatomic (Gordon et al., 2010; Kraus et al., 2015) or laparascopic (O'Donnell et al., 2013) splenectomy have been performed, but no increased risk for certain infections was observed in these studies. There is only one old case report of an asplenic cat that had recovered from *Cytauxzoon felis* infection following treatment with the anti-theilerial drug parvaquone, but showed an increase in piroplasm parasitaemia after splenectomy (Uilenberg et al., 1987); thus, asplenic cats also might be predisposed for certain intracellular bacteria or parasites.

In conclusion, in **asplenic cats**, vaccination protection rate might not be comparable to those of healthy cats. Antibody measurement against FPV infection would be an option to confirm if protection is present. If antibody measurement is not possible, recommendation would be to vaccinate asplenic cats according to the proposed guidelines for healthy cats. When elective splenectomy is planned, vaccination should precede surgery by at least 2 weeks, if possible.

Cats Receiving Immunosuppressive Therapy

Immunosuppressive drugs, such as glucocorticoids, cyclosporine, or tumour chemotherapeutics, are commonly used in cats with various diseases (Rieder and Mischke, 2018; Viviano, 2022). If used short-term, vaccination should be postponed until at least 3 months after the end of the treatment, but some cats require long-term therapy.

Glucocorticoid treatment

Many clinical conditions require long-term glucocorticoid treatment, and the degree of immunosuppression depends on the glucocorticoid dosage used (Greene and Levy, 2012). In many immune-mediated diseases, glucocorticoids are the initial and primary drug of choice and started mostly at high doses. The effects of such high doses of glucocorticoids on the immune system are substantial with effects involving various components of the immune system. The effects on neutrophils include decreases in chemotaxis and margination and impaired phagocytosis and bacterial killing, thus predisposing the patient to infections that can involve many body

tissues. The effects of glucocorticoids on macrophages result in impaired chemotaxis, phagocytosis, and bactericidal activity. Macrophages will also have decreased interleukin-1 production and antigen-processing which will further predispose the animal to infection. Glucocorticoids will cause depressed lymphocyte proliferation, depressed T cell responses, impaired T cell cytotoxicity, depressed interleukin-2 production, and depressed lymphokine production. There is also an influence on immunoglobulin production (Day and Schultz, 2014b; Tizard, 2018b). Patients treated with high doses of glucocorticoids will be even further predisposed to infection if other cytotoxic or immunosuppressive drugs are used simultaneously (Schaer, 2008). In humans, organ transplant recipients receiving high dose glucocorticoids are an important specific group of severely immunocompromised people, and there are specific recommendations on vaccinations (e.g., against influenza) for these patients (Kumar et al., 2011); however, organ transplantation is still not very commonly performed in feline medicine. Dogs treated with prednisolone (2 mg/kg q12h) showed a decrease in the serum concentration of all immunoglobulin classes as well as lower numbers of CD4+ and CD8+ positive T cells and B cells (Rinkardt et al., 1999). One study demonstrated a significant decrease in T cells after short-term use of prednisolone (3 days with a dose between 1.66 and 2.24 mg/kg q24h) over a period of 38 days (Ammersbach et al., 2006).

The exact amount of systemic glucocorticoids and the duration of their administration needed to suppress the immune system in an otherwise healthy cat are not well defined. The immunocompromising effects of glucocorticoid treatment vary, but many clinicians consider a dose of 2 mg/kg prednisolone as sufficiently immunocompromising to raise concerns about the safety of vaccination with modified live-virus vaccines. Glucocorticoids used in lower (but still higher than physiologic) doses also might reduce the immune response to vaccines. In human medicine, glucocorticoid therapy usually does not contraindicate administration of vaccines (not even with modified-live virus vaccines), when glucocorticoid therapy is short-term (less than 2 weeks), is given in only a low to moderate dose, is given as long-term alternate-day treatment with short-acting preparations, is given to maintain physiologic doses (such as replacement therapy in patients with Addison's disease), or is only administered locally (topically to skin or eyes, by aerosol, or by intra-articular, bursal, or tendon injection) (Centers for Disease Control and Prevention, 1993).

Studies on the effect of glucocorticoid therapy on vaccination response in dogs and cats show inconsistent results. One study investigated the effect of oral prednisolone on vaccination against CDV in Beagle puppies and found that doses of 1 mg/kg q24h and 10 mg/kg q24h prednisolone orally over a period of 21 days had no effect on the response to vaccination (Nara et al., 1979). The use of 0.25 mg/kg dexamethasone (which corresponds to a dose of 1.25 mg/kg prednisolone) in dogs before and after the first vaccination against rabies also had no negative effects on the antibody response (Blancou et al., 1981). A study in cats found that glucocorticoid injections (3 times 2.25 mg prednisolone and 0.75 mg dexamethasone intramuscularly 48 h apart) had no effect on the humoral immune response and challenge after vaccination with an inactivated combination vaccine against feline FPV, FHV, and FCV (Povey and Carman, 1997). However, one study assessed the prevalence of antibodies against FPV in cats in Southern Germany and identified factors that were associated with a lack of antibodies in 350 client-owned cats. In this study, glucocorticoid treatment was significantly associated with a lack of antibodies, and cats receiving glucocorticoids for 11 weeks and longer were particularly at risk (Mende et al., 2014a).

In conclusion, if possible, veterinarians should wait at least 3 months after discontinuation of **glucocorticoid therapy** before administering vaccines, especially modified-live virus vaccines, to cats who have received high-dose, systemic glucocorticoids for more than 2 weeks. If continuous long-term glucocorticoid therapy is necessary, vaccinations schedules should be maintained, but inactivated vaccines should be applied, if available. On the other hand, vaccination could be safely considered in well-controlled cats receiving low-dose anti-inflammatory glucocorticoid treatment. Antibody measurement against FPV infection would be a good possibility to confirm that protection against panleukopenia is present in cats treated with glucocorticoids.

Cyclosporine treatment

Cyclosporines are commonly used in cats, such as for feline hypersensitivity dermatitis or autoimmune diseases (Colombo and Sartori, 2018). Cyclosporine depresses lymphocyte function (Cridge et al., 2020) and can interfere with cell-mediated immunity, thus compromising the host defence system against infectious agents, such as intracellular parasites (Schaer, 2008). In 5/10 cats that had been treated with cyclosporine at a daily dose of 20 mg/kg q24h for 4 weeks, an impairment of the cell-mediated immune response was demonstrated (Latimer et al., 1986). It has been shown that cats with high cyclosporine blood concentrations at the time of primary *Toxoplasma gondii* infection can be at risk of developing systemic toxoplasmosis (Lappin et al., 2015; Salant et al., 2021), that cats treated with cyclosporine can develop unusual presentations of toxoplasmosis such as *Toxoplasma gondii*-associated cholecystitis (Lo Piccolo et al., 2019), that latent *Toxoplasma gondii* infection can be reactivated during treatment (Barrs et al., 2006), and that in some cats being treated with cyclosporine, toxoplasmosis **can be** fatal (Last et al., 2004). Cats receiving cyclosporine are also predisposed to other infections, such as systemic *Salmonella* spp. infection (Callegari et al., 2014). It has been suggested that few client-owned cats that had received cyclosporine to block renal transplant rejection had developed clinical signs of upper respiratory tract disease that might have been caused by re-activation of FHV infection. In one study, cats experimentally inoculated with FHV several months previously were administered cyclosporine (or placebo); while clinical signs of re-activated FHV infection occurred in some cats, disease was mild in most of them and did not require specific therapy. These findings suggest that the use of cyclosporine

(at least in the dosage used) is unlikely to induce significant FHV-associated disease in previously infected cats (Lappin et al., 2015).

One study investigated the immunosuppressive effect of cyclosporine on the ability of cats to mount an immune response following vaccination. Thirty-two healthy, immunocompetent adult cats (16 cats/group) were treated with either cyclosporine for 56 days at a dose of 24 mg/kg q24h (more than 3 times the therapeutic dose) or sham-dosed. Prior to treatment, cats had an adequate antibody response to primary vaccination against FPV, FHV, FCV, FeLV, and rabies. Booster vaccination against FPV, FHV, FCV, FeLV and rabies or novel vaccination against FIV were administered 28 days after initiation of treatment with cyclosporine. There were delays/reductions in antibody response to FHV, FeLV, and rabies in treated cats; however, adequate protection was achieved in response to all booster vaccinations. Following primary vaccination with FIV, however, control cats showed a response, but treated cats showed no antibody production. Thus, adult cats treated with high-dose cyclosporine were able to achieve adequate protection following booster vaccination, while in contrast, cats failed to mount a humoral response to a novel vaccination. This suggests that memory B cell immune responses remain intact during high-dose cyclosporine administration in cats, but that primary immune responses are impaired (Roberts et al., 2015).

Thus, in conclusion, booster vaccination can be given to **cats receiving cyclosporine**, but novel vaccinations should be applied before cyclosporine treatment is initiated or postponed until at least 3 months after the end of the treatment. Measurement of FPV antibodies is a good option to confirm that protection against panleukopenia is present.

Tumour chemotherapy

Many of the cytotoxic drugs used for anti-tumour chemotherapy inhibit cell division, and when this occurs, the B and T cells are often destroyed, thus impairing the body's ability to produce antibodies and to allow for cell-mediated immune protection. The immune system of the tumour patient will be further compromised by the concomitant use of other immunosuppressive agents, such as glucocorticoids, and any devastating effect of myelophthisic tumour behaviour (Schaer, 2008).

Administration of chemotherapeutic agents to mice and humans had variable effects on different components of the immune system. For example, lymphocyte depletion in human patients undergoing chemotherapy has been reported, but the degree of lymphocyte depletion appeared to be dependent on the particular chemotherapy protocol (Ten Berge et al., 1984; Sabbioni et al., 1999) . Lymphocyte depletion, specifically, depletion of CD4[+] T cells, can even persist long after completion of chemotherapy (Azuma et al., 1998; Sara et al., 1999). Even though this is described in humans, in FeLV-infected cats with mediastinal lymphoma, chemotherapy did not cause any significant change in the CD4+/CD8+ ratio (Jaroensong et al., 2022). Furthermore, not all chemotherapy agents are equally immunosuppressive. Alkylating agents, such as cyclophosphamide, are particularly prone to cause immunosuppression because of their affinity for destroying rapidly dividing cells, thus impairing the B and T cell response. These effects on the immune system are made even worse by cyclophosphamides´ ability to suppress the bone marrow and cause neutropenia (Schaer, 2008). However, on the other hand, in humans, cyclophosphamide administered at low doses was shown to actually potentiate humoral immunity and decrease immunologic tolerance (Periti and Mini, 1987; Emens et al., 2001). Doxorubicin and related drugs also have different effects on adaptive immune responses, with doxorubicin being immunostimulatory and preserving cell-mediated immunity in some human studies (Roth et al., 1978; Periti and Mini, 1987; Formelli et al., 1988; Ehrke et al., 1989; Gautam et al., 1991; Fornasiero et al., 1992; Emens et al., 2009). The effects of chemotherapy on the humoral immune response can also be variable. In human paediatric oncology patients, pre-existing titres to tetanus, diphtheria, and poliomyelitis were preserved throughout chemotherapy in some, but not all studies (Ridgway and Wolff, 1993; Reinhardt et al., 2003; Zignol et al., 2004). In some studies, the ability of the humoral immune system to respond to vaccination was restored within 3 to 12 months of completing chemotherapy (Oldham et al., 1976; Alanko et al., 1992; Mustafa et al., 1998; Reinhardt et al., 2003) .

In dogs, chemotherapy has been shown to have no effect on pre-existing antibody titres. A prospective study determined the association between tumour chemotherapy and serum CDV, CPV, and rabies virus antibody titres in tumour-bearing dogs, including 21 client-owned dogs with various malignancies and 16 with lymphoma. No significant changes were detected in CDV, CPV, and rabies virus titres following chemotherapy in tumour-bearing dogs. Thus, established immunity to CDV, CPV, and rabies virus from previous vaccination was not significantly compromised by standard chemotherapy (Henry et al., 2001). Another prospective study evaluated the effects of 2 common chemotherapy protocols on T and B cell numbers and humoral immune responses to *de novo* vaccination in 21 dogs with tumours (12 with lymphoma, 9 with osteosarcoma) comparing effects of doxorubicin *versus* multi-drug chemotherapy. Doxorubicin treatment did not cause a significant decrease in T or B cell numbers, whereas treatment with combination chemotherapy caused a significant and persistent decrease in B cell numbers. Antibody titres after vaccination, however, were not significantly different between control and chemotherapy-receiving dogs. These findings suggest that chemotherapy might have less impact on T cell numbers and ability to mount antibody responses in dogs with tumours than previously anticipated and that administration of chemotherapy does not preclude administration of vaccines (Walter et al., 2006).

Few data are available on **cats receiving tumour chemotherapy**, but studies in dogs suggest that chemotherapy might not have a significant impact on immunologic reactions and the ability to mount antibody responses and that administration of chemotherapy does

not preclude the administration of vaccines. However, based on the recommendations in humans, when tumour chemotherapy is being considered, vaccination should ideally precede the initiation of chemotherapy or immunosuppression by at least two weeks or, if not possible, be postponed until at least three months after the end of chemotherapy. If possible, vaccination during chemotherapy should be avoided because antibody responses might be suboptimal.

Cats under General Anaesthesia

Many countries regularly perform spay/neuter and release programs to control the stray cat population. Cats in such situations are commonly very difficult to handle and are released immediately after recovering from anaesthesia. Some of these programs include vaccination of cats while still under anaesthesia for spaying/neutering due to easier handling. Although short-term immunosuppressive effects of anaesthesia and surgery have been described (Kelly, 1980; Kona-Boun et al., 2005), there is no evidence of a clinically relevant influence on the immune response to vaccination (Scherk, 2008). Humoral immune response after vaccination against CDV and CPV between 10 days before and 3 days after surgery was found to be adequate (at least a 4-fold increase in antibody titres) in 17 of 20 dogs (Miyamoto et al., 1995). One prospective study determined the effects of anaesthesia and surgery on antibody development after vaccination in 32 specific-pathogen-free kittens. Kittens were assigned to 1 of 4 treatment groups: neutering at 7, 8, or 9 weeks of age or no neutering. All kittens were inoculated with modified-live virus vaccines against FPV, FHV, and FCV at 8, 11, and 14 weeks of age and inactivated rabies virus at 14 weeks of age. Antibody response of kittens neutered at the time of first vaccination (8 weeks) were not different from those of kittens neutered 1 week before (7 weeks) or 1 week after (9 weeks) the first vaccination or from those of kittens that were not neutered. Anaesthesia and neutering at or near the time of first vaccination with a modified-live virus vaccine did not impair antibody responses in kittens (Reese et al., 2008).

Thus, in conclusion, when necessary (e.g., trap-neuter situation) cats can be vaccinated in the perioperative period. However, if easily possible, vaccination should not be given during **anaesthesia and/or surgery or directly afterward** but should ideally be postponed.

Geriatric cats

Advances in veterinary medicine, nutrition, and client education have increased the life expectancy for domestic cats in recent years (Miele et al., 2020; Churchill and Eirmann, 2021). In a study in the United States, approximately 20% of pet cats were 11 years of age or older (Bellows et al., 2016); and a 2017 study in the UK showed a median age of 6.2 years in cats presenting to veterinary clinics, with cats aged more than 8 years representing more than 40% of feline consultations (Sánchez-Vizcaino et al., 2017). Ageing is a continuous and slow process that compromises the normal functioning of various organs and systems in both qualitative and quantitative terms (Malaguarnera et al., 2000), and has been defined as a complex process in which the individual suffers from a decline in physical condition, organ, sensory and mental function, as well as immune response (Burns, 2004; Dowgray et al., 2022). Obviously, there is a great individual variation between biological and chronological age and how the body systems age in each individual, meaning that geriatric abnormalities or diseases can appear earlier in some cats and never appear in others. Thus, feline aging is considered a multifaceted process that results in a progressive series of life stages, from conception to senescence. It is influenced by the host's genetics, plus innumerable internal and external factors and results in the progressive decline in the ability to maintain homeostasis when challenged by physiologic and environmental stressors (Bellows et al., 2016). These factors include previous injuries, disease, nutritional status, and environmental challenges, and thus, every cat ages slightly differently.

It has been proposed to classify older cats as mature (7–10 years), seniors (11–14 years), and geriatric or super senior (> 15 years) (Vogt et al., 2010). Seniority in animals is defined to start at an age that is 25% below the average life expectancy within the species/breed which would be calculated as 11 years in cats (Epstein et al., 2005). Although general senior care guidelines (Quimby et al., 2021) have been published by the American Association of Feline Practitioners (AAFP) (Ray et al., 2021) and the American Animal Hospital Association (AAHA) (Epstein et al., 2005) and implementation of senior/geriatric health care program in veterinary practice has been proposed (Fortney, 2012), so far, there are no specific vaccination recommendations for senior or geriatric cats, and there is a general lack of knowledge if geriatric cats have special vaccination needs.

Ageing and geriatric decline of body systems can lead to a decrease in immune function (immunosenescence) (Pastoret, 2007; HogenEsch and Thompson, 2010; Schultz et al., 2010; Day, 2010) and also to a pro-inflammatory state (inflammageing) plus the presence of degenerative, neoplastic, or inflammatory/immune-mediated diseases, which all can have an impact on the susceptibility to infectious diseases and/or produce an abnormal or decreased response to vaccination (Ginaldi et al., 2001; Dall´Ara, 2003; Plowden et al., 2004; Thiry and Horzinek, 2007; Kumar and Burns, 2008; HogenEsch and Thompson, 2010; Dewitt and Luebke, 2018).

"Immunosenescence" has been defined as a multifactorial complex of changes that occurs in the immune system of elderly individuals that predisposes them to increased morbidity and mortality to infection and age-related pathology. It has recently been suggested that immunological changes in immunosenescence resemble those observed following chronic stress or corticosteroid treatment (Bauer and DeLa Fuente, 2016). Immunosenescence can result in a reduced ability to screen for neoplastic cells and fight infection (Day, 2010) and

thus, render individuals more susceptible to certain infections; for example, cystitis in younger cats in less than 15% of cases is caused by bacterial infection, compared with up to 50% in cats 10 years or older (Lekcharoensuk et al., 2001; Dorsch et al., 2016). Immunosenescence could also reduce the ability to efficiently mount an immune response after vaccine administration. "Inflammageing" has been defined as the effects of a lifetime constant antigenic challenge and associated production of inflammatory mediators that can trigger the onset of inflammatory disease in older individuals. Immunosenescence and inflammageing have also been shown to occur in cats, but there are no data about the effects of these conditions on the immune responses after the vaccination.

Several immunological differences have been demonstrated in some studies in senior and geriatric cats when compared to younger adult cats (Day, 2010; Miele et al., 2020), including lower number of circulating leucocytes (lymphocytes, CD4+ T cells, CD8+ T cells, B cells, CD56+ NK cells, and eosinophils), elevated concentrations of IgM and IgA, lower levels of insulin-like growth factor (which can be associated to lower numbers of CD4+ T cells), reduced blood lymphocyte blastogenic responses to stimulation with several mitogens, and increased monocyte production of pro-inflammatory cytokines (determined by mRNA levels) (Day, 2010). These changes demonstrate some alteration of the immune response, but do not tackle all elements of immunosenescence as described in general in geriatric mammals, such as the innate immune response that might be unaltered or even increased (Pawelec et al., 2010), the ability to mount a primary serum antibody response to a novel antigen being unaltered despite a decrease in B cell numbers, presence of antibodies with lower affinity (Pawelec et al., 2010), quicker antibody titre decrease (HogenEsch and Thompson, 2010), the ability to adequately retain B cell memory and serum antibody concentrations, that however, less effectively respond to primary immunization, decrease in the CD4+/CD8+ ratio, decreased number of naive T cells (Pawelec et al., 2010), and increase in percentage of presumed memory CD4+ and CD8+ T cells.

In humans, specific guidelines for elderly people (generally > 60 years of age) exist, and increased vulnerability to infection of the elderly makes them a particularly important target population for vaccination. Most vaccines are considered less immunogenic and efficient in elderly people because of age-related changes in the immune system. Various strategies, such as the use of specifically designed vaccines for elderly people (e.g., novel adjuvants and administration routes) have been proposed. As antibody titres are generally lower in the elderly and decline faster, regular booster vaccinations are considered essential to ensure protection (Weinberger and Grubeck-Loebenstein, 2012).

In cats, to this point no studies have been published on the response of senior or geriatric cats to vaccination, and the question arises if either immunosenescence or inflammageing might have an impact on immunity which should lead to changes in vaccination protocols in old cats. There are no data that would support the idea of infectious diseases being more common in senior or geriatric cats, and the incidence of infectious diseases preventable by vaccination in senior and geriatric cats is generally considered low. Old cats rarely die or present with signs of those infections (Kruse et al., 2011; Riemer et al., 2016). On the other hand, it is also not known whether vaccine boosters could worsen a pro-inflammatory state in a senior or geriatric cat, and thus, reducing the number of booster vaccinations would seem appropriate. In addition, many senior or geriatric cats are diagnosed with chronic inflammatory or immune-mediated diseases, such as chronic gingivitis or periodontal disease, chronic kidney disease, inflammatory bowel disease, inflammatory liver disease, or pancreatitis, on which frequent vaccinations might have a negative impact.

Although so far no studies have been performed on the response of senior or geriatric cats to vaccination, duration of immunity (DOI) studies have shown long-term immunity against FPV, FHV, and FCV (Scott and Geissinger, 1997; Scott and Geissinger, 1999; Lappin et al., 2002), and experimental studies have demonstrated that immunity persists for years showing that immunological memory to core vaccines is adequate as well as the immunological response to boosters (Schultz et al., 2010; Day et al., 2016). Based on these experimental studies and expert opinion, healthy geriatric cats properly vaccinated should receive boosters at recommended intervals based on published guidelines and following assessment of individual risk (Hartmann et al., 2022). On the other hand, there is some evidence that older cats might not respond efficiently to novel antigens that are administered for the first time. This has been shown with rabies vaccine in dogs but could be presumed for any other antigen. Older dogs vaccinated for the first time against rabies showed lower antibody levels compared to younger dogs, in general with titres below 0.5 IU/ IU/ml (Kennedy et al., 2007). In addition, it is known that the number of naive T cells decreases with increasing age also resulting in an impaired immune response to new antigens (Day, 2010; HogenEsch et al., 2004; Dewitt and Luebke, 2018).

Thus, in conclusion, based on these findings, if healthy **senior or geriatric cats** that need to be vaccinated against a novel pathogen for the first time (travelling, moving, changing life style), even if the regular vaccination schedule consists of one injection (e.g., rabies), a single dose should not be considered enough to ensure a proper immunisation, and a second dose is recommended in these animals at a 3-to-4-week interval. Alternatively, FPV and rabies antibodies could be measured after the first injection to verify that protection is adequate. Cats that need regular re-vaccinations should be vaccinated according to the proposed guidelines for healthy young cats.

Acknowledgement

References

Ackley CD, Yamamoto JK, Levy N, et al (1990): Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus. J Virol 64, 598–606.

Alanko S, Pelliniemi TT, Salmi TT (1992): Recovery of blood B lymphocytes and serum immunoglobulins after chemotherapy for childhood acute lymphoblastic leukemia. Cancer 69, 1481–1486.

Alter MJ, Farrero MS, Maynard JG (1986): Impact of infection control strategies on the incidence of dialysis-associated hepatitis in the United States. J Infect Dis 153, 1149–1151.

Ammersbach MA, Kruth SA, Sears W, et al (2006): The effect of glucocorticoids on canine lymphocyte marker expression and apoptosis. J Vet Intern Med 20, 1166–1171.

Anema A, Mills E, Montaner J, et al (2008): Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis. HIV Med 9, 57–61.

Atashili J, Kalilani L, Adimora AA (2006): Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: A meta-analysis. BMC Infect Dis 6, 138.

Azuma E, Nagai M, Qi J, et al (1998): CD4+ T-lymphocytopenia in long-term survivors following intensive chemotherapy in childhood cancers. Med Pediatr Oncol 30, 40–45.

Bailiff NL, Nelson RW, Feldman EC, et al (2006): Frequency and risk factors for urinary tract infection in cats with diabetes mellitus. J Vet Intern Med 20, 850–855.

Bandecchi P, Dell'Omodarme M, Magi M, et al (2006): Feline leukaemia virus (FeLV) and feline immunodeficiency virus infections in cats in the Pisa district of Tuscany, and attempts to control FeLV infection in a colony of domestic cats by vaccination. Vet Rec 158, 555–557.

Barlough JE, Ackley CD, George JW, et al (1991): Acquired immune dysfunction in cats with experimentally induced feline immunodeficiency virus infection: Comparison of short-term and long-term infections. J Acquir Immune Defic Syndr 4, 219.

Barlough JE, North TW, Oxford CL, et al (1993): Feline immunodeficiency virus infection of cats as a model to test the effect of certain in vitro selection pressures on the infectivity and virulence of resultant lentivirus variants. Antiviral Res 22, 259–272.

Barrs VR, Martin P, Beatty JA (2006): Antemortem diagnosis and treatment of toxoplasmosis in two cats on cyclosporin therapy. Aust Vet J 84, 30–35.

Bauer ME, DeLa Fuente M (2016): The role of oxidative and inflammatory stress and persistent viral infections in immunosenescence. Mech Ageing Dev 158, 27-37. doi: 10.1016/j.mad.2016.01.001. Epub 2016 Jan 7. PMID: 26773975 Review.

Beam TR Jr, Crigler ED, Goldman JK, et al (1980): Antibody response to polyvalent pneumococcal polysaccharide vaccine in diabetics. JAMA 244, 2621–2624.

Beck CR, McKenzie BC, Hashim AB, et al (2012): Influenza vaccination for immunocompromised patients: Systematic review and meta-analysis by etiology. J Infect Dis 206, 1250–1259.

Bęczkowski PM, Litster A, Lin TL, Mellor DJ, Willett BJ, Hosie MJ (2015): Contrasting clinical outcomes in two cohorts of cats naturally infected with feline immunodeficiency virus (FIV). Vet Microbiol 176, 50–60.

Bellini WJ, Rota JS, Greer PW, et al (1992): Measles vaccination death in a child with severe combined immunodeficiency: report of a case. Lab Investig 66, 91.

Bellows J, Center S, Daristotle L, et al (2016): Evaluating aging in cats: how to determine what is healthy and what is disease. J Feline Med Surg 18, 551–570.

Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R (2020): Type 2 Diabetes and its impact on the immune system. Curr Diabetes Rev 16, 442–449.

Bergmann M, Schwertler S, Speck S, et al (2019): Antibody response to feline panleukopenia virus vaccination in cats with asymptomatic retrovirus infections: a pilot study. J Feline Med Surg 21, 1094–1101.

Bishop SA, Williams NA, Gruffydd-Jones TJ, et al (1992a): An early defect in primary and secondary T-cell responses in asymptomatic cats during feline immunodeficiency (FIV) virus infection. Clin Exp Immunol 90, 491–496.

Bishop SA, Williams NA, Gruffydd-Jones TJ, et al (1992b): Impaired T-cell priming and proliferation in cats infected with feline leukemia virus. AIDS 6, 287.

Blancou J, Milward F, Toma B (1981): Vaccination against rabies in carnivores treated with corticoids. Rec Med Vet 1981, 631–657.

Brown CA, Elliott J, Schmiedt CW, et al (2016): Chronic kidney disease in aged cats: Clinical Features, Morphology, and Proposed Pathogeneses. Vet Pathol 53, 309–326.

Burns EA (2004): Effects of aging on immune function. J Nutr Health Aging 8, 9–18.

Callegari C, Palermo G, Greco MF, et al (2014): Pneumonia associated with *Salmonella* spp. infection in a cat receiving cyclosporine. Schweiz Arch Tierheilkd 156, 499–503.

Calvert CA, Dawe D, Leifer CE, et al (1982): Lymphocyte blastogenesis in dogs with lymphosarcoma. Am J Vet Res 43, 94–101.

Cavalcante LTF, Muniz CP, Jia H, Augusto AM, Troccoli F, Medeiros SO, Dias CGA, Switzer WM, Soares MA, Santos AF (2018): Clinical and molecular features of feline foamy virus and feline leukemia virus co-infection in naturally-infected cats. Viruses 10, 702.

Centers for Disease Control and Prevention (1993): Recommendations of the Advisory Committee on Immunization Practices (ACIP). Use of vaccines and immune globulins in persons with altered immunocompetence. MMWR 42, 1–18.

Churchill JA, Eirmann L (2021): Senior pet nutrition and management. Vet Clin N Am Small Anim Pract 51, 635–651.

Colombo S, Sartori R (2018): Ciclosporin and the cat: Current understanding and review of clinical use. J Feline Med Surg 20, 244–255.

Cosio FG, Giebink GS, Le CT, et al (1981): Pneumococcal vaccination in patients with chronic renal disease and renal allograft recipients. Kidney Int 20, 254–258.

Cridge H, Kordon A, Pinchuk LM, Wills RW, Thomason JM, Mackin AJ, Archer TM (2020): Effects of cyclosporine on feline lymphocytes activated in vitro. Vet Immunol Immunopathol 219, 109962.

Dall'Ara P (2003): Immune system and ageing in the dog: Possible consequences and control strategies. Vet Res Commun 27, 535–542.

DaRoza G, Loewen A, Djurdjev O, et al (2003): Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: Earlier is better. Am J Kidney Dis 42, 1184–1192.

Datz CA (2010): Noninfectious causes of immunosuppression in dogs and cats. Vet Clin North Am Small Anim Pract 40, 459–467.

Dawson S, Smyth NR, Bennett M, et al (1991): Effect of primary-stage feline immunodeficiency virus infection on subsequent feline calicivirus vaccination and challenge in cats. AIDS 5, 747–750.

Day MJ (2010): Ageing, immunosenescence and inflammageing in the dog and cat. J Comp Pathol 142, 60–69.

Day MJ, Horzinek MC, Schultz RD, et al (2016): WSAVA Guidelines for the vaccination of dogs and cats. J Small Anim Pract 57, 4–8.

Day MJ, Schultz RD (2014a): Cancer immunology and immune system neoplasia. In: Day MJ, Schultz RD (eds): Veterinary Immunology – Principles and Practice, 2nd ed., Boca Raton, Florida USA: CRC Press Taylor & Francis Group: 167–179.

Day MJ, Schultz RD (2014b): Immunodeficiency. In: Day MJ, Schultz RD (eds): Veterinary Immunology—Principles and Practice, 2nd ed., Boca Raton, Florida USA: CRC Press Taylor & Francis Group: 221–231.

DeBey MC (2010): Primary immunodeficiencies of dogs and cats. Vet Clin North Am Small Anim Pract 40, 425–438.

DeWitt JC, Luebke RW (2018): Immunological aging, in: Immune system toxicology. In: McQueen CA (ed.): Comprehensive Toxicology, 3rd ed. Oxford, England: Elsevier: 272–281.

Dodds WJ (2002): Complementary and alternative veterinary medicine: The immune system. Clin Tech Small Anim Pract 17, 58-63.

Dorsch R, Zellner F, Schulz B, Sauter-Louis C, Hartmann K (2016): Evaluation of meloxicam for the treatment of obstructive feline idiopathic cystitis. J Feline Med Surg 18, 925-933.

Dowgray N, Pinchbeck G, Eyre K, Biourge V, Comerford E, German AJ (2022): Aging in cats: Owner observations and clinical finding in 206 mature cats at enrolment to the cat prospective aging and welfare study. Front Vet Sci 9, 859041.

Dutta SK, Novilla MN, Bumgardner MK, Ingling A (1978): Lymphocyte responsiveness to mitogens and quantitation of T and B lymphocytes in canine malignant lymphoma. Am J Vet Res 39, 455-458.

Ehrke MJ, Mihich E, Berd D, et al (1989): Effects of anticancer drugs on the immune system in humans. Semin Oncol 16, 230–253.

Emens LA, Asquith JM, Leatherman JM, et al (2009): Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: A chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 27, 5911–5918.

Emens LA, Machiels JP, Reilly RT, et al (2001): Chemotherapy: Friend or foe to cancer vaccines? Curr Opin Mol Ther 3, 77–84.

Epstein M, Kuehn NF, Landsberg G, et al (2005): AAHA senior care guidelines for dogs and cats. J Am Anim Hosp Assoc 41, 81–91.

European Advisory Board on Cat Diseases (ABCD). Feline Immunodeficiency. May 2017. Available online: http://www.abcdcatsvets.org/feline-immunodeficiency/ (accessed on 14 March 2022).

European Advisory Board on Cat Diseases (ABCD). Feline Leukaemia Virus Infection. November 2018. Available online: http://www.abcdcatsvets.org/feline-leukaemia-virus-infection/ (accessed on 14 March 2022).

European Advisory Board on Cat Diseases (ABCD). Infectious Diseases in Shelter Situations and Their Management. April 2021a. Available online: http://www.abcdcatsvets.org/infectious-diseases-in-shelter-situations-and-their-management/ (accessed on 14 March 2022).

European Advisory Board on Cat Diseases (ABCD). Vaccination and antibody titre testing. 2021b. Available online: http://www.abcdcatsvets.org/vaccination-and-antibody-titre-testing/ (accessed on 14 March 2022).

Feery BJ, Hartman LJ, Hampson AW, et al (1983): Influenza immunization in adults with diabetes mellitus. Diabetes Care 6, 475–478.

Finch NC, Syme HM, Elliott J (2016): Risk factors for development of chronic kidney disease in cats. J Vet Intern Med 30, 602–610.

Foley JE, Leutenegger CM, Dumler JS, et al (2003): Evidence for modulated immune response to *Anaplasma phagocytophila sensu lato* in cats with FIV-induced immunosuppression. Comp Immunol Microbiol Infect Dis 26, 103–113.

Formelli F, Rossi C, Sensi ML, et al (1988): Potentiation of adoptive immunotherapy by cis-diamminedichloroplatinum(II), but not by doxorubicin, on a disseminated mouse lymphoma and its association with reduction of tumor burden. Int J Cancer 42, 952–957.

Fornasiero MC, Ferrari M, Gnocchi P, et al (1992): Immunodepressive activity of FCE 23762 on humoral and cell-mediated immune responses in normal mice: Comparison with doxorubicin. Agents Actions 37, 311–318.

Fortney, WD (2012): Implementing a successful senior/geriatric health care program for veterinarians, veterinary technicians, and office managers. Vet Clin Small Anim 42, 823–834.

Franchini M (1990): Die Tollwutimpfung von mit felinem Leukämivirus infizierten Katzen (Rabies vaccination in cats infected with feline leukemia virus). Veterinary Dissertation, Dr. med. vet., University of Zurich, Zurich, Switzerland 1990.

Gautam SC, Chikkala NF, Ganapathi R, et al (1991): Combination therapy with adriamycin and interleukin 2 augments immunity against murine renal cell carcinoma. Cancer Res 51, 6133–6137.

Giebink GS, Le CT, Cosio FG, et al (1981): Serum antibody responses of high-risk children and adults to vaccination with capsular polysaccharides of *Streptococcus pneumoniae.* Rev Infect Dis 3, 168–178.

Ginaldi L, Loreto MF, Corsi MP, et al (2001): Immunosenescence and infectious diseases. Microbes Infect 3, 851–857.

Goorhuis A, Garcia-Garrido HM, Vollaard AM (2020): Vaccination of immunocompromised patients: When and when not to vaccinate. Ned Tijdschr Voor Geneeskd 164, D5299.

Gordon SS, McClaran JK, Bergman PJ, et al (2010): Outcome following splenectomy in cats. J Feline Med Surg 12, 256–261.

Govaert TM, Sprenger MJ, Dinant GJ, et al (1994): Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial. Vaccine 12, 1185–1189.

Greco DS, Harpold LM (1994): Immunity and the endocrine system. Vet Clin North Am Small Anim Pract 24, 765–782.

Greene CE, Levy JK (2012): Immunoprophylaxis. In: Greene CE (ed.): Infectious Diseases of the Dog and Cat. 4th ed. St Louis, MO: Saunders: 1163–1205.

Hanlon MA, Marr JM, Hayes KA, et al (1993): Loss of neutrophil and natural killer cell function following feline immunodeficiency virus infection. Viral Immunol 6, 119–124.

Hartmann K (2012): Feline leukemia virus infection. In: Greene CE (ed.): Infectious Diseases of the Dog and Cat. 4th ed. St Louis, MO: Saunders: 108–136.

Hartmann K (2014): Management of feline retrovirus-infected cats. In: Kirk´s Current Veterinary Therapy XV. St Louis, MO: Saunders: 1275–1283.

Hartmann K, Hofmann-Lehmann R (2020): What's new in feline leukemia virus infection. Vet Clin N Am Small Anim Pract 50, 1013–1036.

Hartmann K, Möstl K, Lloret A, et al (2022): Vaccination of Immunocompromised Cats. Viruses 14(5).

Henry CJ, McCaw DL, Brock KV, et al (2001): Association between cancer chemotherapy and canine distemper virus, canine parvovirus, and rabies virus antibody titers in tumor-bearing dogs. J Am Vet Med Assoc 219, 1238–1241.

Hoffmann-Fezer G, Mortelbauer W, Hartmann K, et al (1996): Comparison of T-cell subpopulations in cats naturally infected with feline leukaemia virus or feline immunodeficiency virus. Res Vet Sci 61, 222–226.

Hoffmann-Fezer G, Thum J, Ackley C, et al (1992): Decline in CD4+ numbers in cats with naturally acquired feline immunodeficiency virus infection. J Virol 66, 1484.

Hofmann-Lehmann R, Holznagel E, Aubert A, et al (1995): Recombinant FeLV vaccine: Long-term protection and effect on course and outcome of FIV infection. Vet Immunol Immunopathol 46, 127–137.

HogenEsch H, Thompson S (2010): Effect of ageing on the immune response of dogs to vaccines. J Comp Path 142, 74–77.

HogenEsch H, Thompson S, Dunham A, Ceddia M, Hayek M (2004): Effect of age on immune parameters and the immune response of dogs to vaccines: a cross-sectional study. Vet Immunol Immunopathol 97, 77-85.

Hosie MJ, Addie D, Belak S, et al (2009): Feline immunodeficiency. ABCD guidelines on prevention and management. J Feline Med Surg 11, 575–584.

Hosie MJ, Jarrett O (1990): Serological response of cats to feline immunodeficiency virus. AIDS 4, 215–220.

Hulme-Moir KL1, Barker EN, Stonelake A, et al (2010): Use of real-time quantitative polymerase chain reaction to monitor antibiotic therapy in a dog with naturally acquired *Mycoplasma haemocanis* infection. J Vet Diagn Invest 22, 582–587.

Jablonka A, Rossler S, Pletz MW, Schleenvoigt BT (2019): Vaccination of the immunocompromised patient. MMW Fortschr Med 161, 56–60.

Jaroensong T, Piamwaree J, Sattasathuchana P (2022): Effects of chemotherapy on hematological parameters and CD4(+)/CD8(+) ratio in cats with mediastinal lymphoma and seropositive to feline leukemia virus. Animals 12, 223.

Johnson DW, Fleming SJ (1992): The use of vaccine in renal failure. Clin Pharmacokin 22, 434–446.

Kano A (2015): Tumor cell secretion of soluble factor(s) for specific immunosuppression. Scientific reports 5, 8913.

Karayannopoulou M, Anagnostou T, Margariti A, et al (2017): Evaluation of blood T-lymphocyte subpopulations involved in host cellular immunity in dogs with mammary cancer. Vet Immunol Immunopathol 186, 45–50.

Kelly GE (1980): The effect of surgery in dogs on the response to concomitant distemper vaccination. Aust Vet J 56, 556-557.

Kemming G, Messick JB, Mueller W, et al (2004): Can we continue research in splenectomized dogs? *Mycoplasma haemocanis*: Old problem–new insight. Eur Surg Res 36, 198–205.

Kennedy LJ, Luntb M, Barnes A, et al (2007): Factors influencing the antibody response of dogs vaccinated against rabies. Vaccine 25, 8500–8507.

Kim R, Emi M, Tanabe K (2006): Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology 119, 254–264.

Kona-Boun JJ, Silim A, Troncy EJ (2005): Immunologic aspects of veterinary anesthesia and analgesia. Am Vet Med Assoc 226(3), 355-363. doi: 10.2460/javma.2005.226.355.

Kraft W (1996): Congenital immune deficiency diseases. Tierarztl Prax 24, 529–531.

Krakowka S, Olsen RG, Axthelm MK, Rice J, Winters K (1982): Canine parvovirus infection potentiates canine distemper encephalitis attributable to modified live-virus vaccine. J Am Vet Med Assoc 180, 137–139.

Kraus KA, Clifford CA, Davis GJ, et al (2015): Outcome and prognostic indicators in cats undergoing splenectomy for splenic mast cell tumors. J Am Anim Hosp Assoc 51, 231–238.

Kruse BD, Unterer S, Horlacher K, Sauter-Louis C, Hartmann K (2011): Feline panleukopenia – different course of disease in cats younger than versus older than 6 months of age? Tierarztl Prax 39, 237–242.

Kumar D, Blumberg EA, Danziger-Isakov L, et al (2011): Influenza vaccination in the organ transplant. Am J Transplant 11, 2020–2030.

Kumar R, Burns EA (2008): Age-related decline in immunity: Implications for vaccine responsiveness. Expert Rev Vaccines 7, 467–479.

Lappin MR, Andrews J, Simpson D, et al (2002): Use of serologic tests to predict resistance to feline herpesvirus 1, feline calicivirus, and feline parvovirus infection in cats. J Am Vet Med Assoc 220, 38–42.

Lappin MR, Basaraba RJ, Jensen WA (2006): Interstitial nephritis in cats inoculated with Crandell Rees feline kidney cell lysates. J Feline Med Surg 8, 353–356.

Lappin MR, Jensen WA, Jensen TD, et al (2005): Investigation of the induction of antibodies against Crandell-Rees feline kidney cell lysates and feline renal cell lysates after parenteral administration of vaccines against feline viral rhinotracheitis, calicivirus, and panleukopenia in cats. Am J Vet Res 66, 506–511.

Lappin MR, VanLare KA, Seewald W, et al (2015): Effect of oral administration of cyclosporine on Toxoplasma gondii infection status of cats. Am J Vet Res 76, 351–357.

Last RD, Suzuki Y, Manning T, Lindsay D, Galipeau L, Whitbread TJ (2004): A case of fatal systemic toxoplasmosis in a cat being treated with cyclosporin A for feline atopy. Vet Dermatol 15(3), 194-198. doi: 10.1111/j.1365-3164.2004.00371.x.

Latimer KS, Rakich PM, Purswell BJ, et al (1986): Effects of cyclosporin A administration in cats. Vet Immunol Immunopathol 11, 161–173.

Lawrence CE, Callanan JJ, Willett BJ, et al (1995): Cytokine production by cats infected with feline immunodeficiency virus: a longitudinal study. Immunology 85, 568–574.

Lederman MM, Schiffman G, Rodman HM (1981): Pneumococcal immunization in adult diabetics. Diabetes 30, 119–121.

Lehane DE, Lane M (1974): Immunocompetence in advanced cancer patients prior to chemotherapy. Oncology 30, 458–466.

Lehmann R, Franchini M, Aubert A, et al (1991): Vaccination of cats experimentally infected with feline immunodeficiency virus, using a recombinant feline leukemia virus vaccine. J Am Vet Med Assoc 199, 1446–1452.

Lehmann R, von Beust B, Niederer E, et al (1992): Immunization-induced decrease of the CD4+:CD8+ ratio in cats experimentally infected with feline immunodeficiency virus. Vet Immunol Immunopathol 35, 199–214.

Lekcharoensuk C, Osborne CA, Lulich JP (2001): Epidemiologic study of risk factors for lower urinary tract diseases in cats. J Am Vet Med Assoc 218, 1429–1435.

Levy J, Crawford C, Hartmann K, et al (2008): 2008 American Association of Feline Practitioners' feline retrovirus management guidelines. J Feline Med Surg 10, 300–316.

Linenberger ML, Deng T (1999): The effects of feline retroviruses on cytokine expression. Vet Immunol Immunopathol 72, 343–368.

Linneman CC Jr, First MR (1979): Risk of pneumococcal infections in renal transplant patients. JAMA 241, 2619–1621.

Linneman CC Jr, First MR, Schiffman G (1981): Response to pneumococcal vaccine in renal transplant and hemodialysis patients. Arch Intern Med 141, 1637–1640.

Linneman CC Jr, First MR, Schiffman G (1986): Revaccination of renal transplant and hemodialysis recipients with pneumococcal vaccine. Arch Intern Med 146, 1554–1556.

Ljungman P (2012): Vaccination of immunocompromised patients. Clin Microbiol Infect 18 (Suppl. 5), 93–99.

Lombardi M, Pizzarelli F, Righi M, et al (1992): Hepatitis B vaccination in dialysis patients and nutritional status. Nephron 61, 266–268.

Lo Piccolo F, Busch K, Palić J, Geisen V, Hartmann K, Unterer S (2019): Toxoplasma gondii-associated cholecystitis in a cat receiving immunosuppressive treatment. Tierarztl Prax Ausg K Kleintiere Heimtiere 47(6), 453-457. doi: 10.1055/a-1020-3775.

Lutz H, Addie D, Belak S, et al (2009): Feline leukaemia. ABCD guidelines on prevention and management. J Feline Med Surg 11,

565–574.

Luxi N, Giovanazzi A, Capuano A, Crisafulli S, Cutroneo PM, Fantini MP, Ferrajolo C, Moretti U, Poluzzi E, Raschi E, et al (2021): COVID-19 Vaccination in pregnancy, paediatrics, immunocompromised patients, and persons with history of allergy or prior SARS-CoV-2 infection: Overview of current recommendations and pre- and post-marketing evidence for vaccine efficacy and safety. Drug Saf 44, 1247–1269.

Malaguarnera L, Ferlito L, Imbesi R, et al (2000): Immunosenescence: A review. Arch Gerontol Geriatr 32, 1–14.

Mayer-Roenne B, Goldstein RE, Erb HN (2007): Urinary tract infections in cats with hyperthyroidism, diabetes mellitus and chronic kidney disease. J Feline Med and Surg 9, 124–132.

McLeland S, Quimby J, Lappin MR (2019): Alpha-enolase staining patterns in the renal tissues of cats with and without chronic kidney disease. Vet Immunol Immunopathol 212, 23-26.

Mende K, Stuetzer B, Sauter-Louis C, et al (2014a): Prevalence of antibodies against feline panleukopenia virus in client-owned cats in Southern Germany. Vet J 199, 419–423.

Mende K, Stuetzer B, Truyen U, et al (2014b): Evaluation of an in-house dot enzyme-linked immunosorbent assay to detect antibodies against feline panleukopenia virus. J Feline Med Surg 16, 805–811.

Meyer KE (2001): Vaccine-associated adverse events. Vet Clin North Am Small Anim Pract 31, 493–514.

Miele A, Sordo L, Gunn-Moore DA (2020): Feline Aging. Promoting Physiologic and Emotional Well-Being. Vet Clin Small Anim 50, 719–748. https://doi.org/10.1016/j.cvsm.2020.03.004

Mitus A, Holloway A, Evans AE, et al (1962): Attenuated measles vaccine in children with acute leukemia. Am J Dis Child 103, 243–248.

Miyamoto T, Taura Y, Une S, et al (1995): Immunological responses after vaccination pre- and post-surgery in dogs. J Vet Med Sci 57, 29–32.

Mucha J, Rybicka A, Dolka I (2016): Immunosuppression in dogs during mammary cancer development. Vet Pathol 53, 1147-1153.

Muneer MA, Farah IO, Newman JA, et al (1988): Immunosuppression in animals. Br Vet J 144, 288–301.

Mustafa MM, Buchanan GR, Winick NJ, et al (1998): Immune recovery in children with malignancy after cessation of chemotherapy. J Pediatr Hematol Oncol 20, 451–457.

Nara PL, Krakowka S, Powers TE (1979): Effects of prednisolone on the development of immune responses to canine distemper virus in beagle pups. Am J Vet Res 40, 1742–1747.

National Center for Immunization and Respiratory Diseases (2011): General recommendations on immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 60, 1–64.

Negahdaripour M, Shafiekhani M, Moezzi SMI, Amiri S, Rasekh S, Bagheri A, Mosaddeghi P, Vazin A (2021): Administration of COVID-19 vaccines in immunocompromised patients. Int Immunopharmacol 99, 108021.

Nieman LK, Biller BMK, Findling JW, et al (2015): Treatment of Cushing's syndrome: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 100, 2807–2831.

Nishimura Y, Shimojima M, Sato E, et al (2004): Downmodulation of CD3 expression in CD8 T cells of feline immunodeficiency virus-infected cats. J Gen Virol 85, 2585–2589.

Novotney C, English RV, Housman J, et al (1990): Lymphocyte population changes in cats naturally infected with feline immunodeficiency virus. AIDS 4, 1213–1208.

O'Donnell E, Mayhew P, Culp W, et al (2013): Laparoscopic splenectomy: operative technique and outcome in three cats. J Feline Med Surg 15, 48–52.

Ohno K, Watari T, Goitsuka R, et al (1992): Altered surface antigen expression on peripheral blood mononuclear cells in cats infected with feline immunodeficiency virus. J Vet Med Sci 54, 517–522.

Oldham RK, Weiner RS, Mathe G, et al (1976): Cell-mediated immune responsiveness of patients with acute lymphocytic leukemia in remission. Int J Cancer 17, 326–337.

Pastoret PP (2007): Challenges and issues of early life vaccination in animals and humans. J Comp Pathol 137, 2–3.

Pawelec G, Larbi A, Derhovanessian E (2010): Senescence of the Human Immune System. J Comp Path 142, 39–44.

Periti P, Mini E (1987): Immunomodulation by cancer chemotherapeutic agents. Chemioterapia 6, 399–402.

Pesanti EL (2001): Immunologic defects and vaccination in patients with chronic renal failure. Infect Dis Clin North Am 15, 813–832.

Pitorri F, Dell'Orco M, Carmichael N, et al (2012): Use of real-time quantitative PCR to document successful treatment of *Mycoplasma haemocanis* infection with doxycycline in a dog. Vet Clin Pathol 41, 493–496.

Plowden J, Renshaw-Hoelscher M, Engleman C, et al (2004): Innate immunity in aging: Impact on macrophage function. Aging Cell 3, 161–167.

Povey RC, Carman PS (1997): Factors influencing the outcome of vaccination. In: Technical basis of vaccination. In: Pastoret PP, Blancou J, Vannier P, Verschueren C (eds.): Veterinary vaccinology. Amsterdam, Niederlande: Elsevier Science B.V.: 540-545, references: 54-64.

Quackenbush SL, Donahue PR, Dean GA, et al (1990): Lymphocyte subset alterations and viral determinants of immunodeficiency disease induction by the feline leukemia virus FeLV-FAIDS. J Virol 64, 5465–5474.

Quimby J, Gowland S, Carney HC, DePorter T, Plummer P, Westropp J (2021): AAHA/AAFP Feline Life Stage Guidelines. J Feline Med Surg 23, 211–233.

Ray M, Carney HC, Boynton B, Quimby J, Robertson S, St Denis K, Tuzio H, Wright B (2021): AAFP Feline Senior Care Guidelines. J Feline Med Surg 23, 613–638.

Reese MJ, Patterson EV, Tucker SJ, et al (2008): Effects of anesthesia and surgery on serologic responses to vaccination in kittens. J Am Vet Med Assoc 233, 116–121.

Reinhardt D, Houliara K, Pekrun A, et al (2003): Impact of conventional chemotherapy on levels of antibodies against vaccine preventable diseases in children treated for cancer. Scand J Infect Dis 35, 851–857.

Reubel GH, Dean GA, George JW, et al (1994): Effects of incidental infections and immune activation on disease progression in experimentally feline immunodeficiency virus-infected cats. J Acquir Immune Defic Syndr 7, 1003–1015.

Rideout BA, Moore PE, Pedersen NC (1992): Persistent upregulation of MHC class II antigen expression on T-lymphocytes from cats experimentally infected with feline immunodeficiency virus. Vet Immunol Immunopathol 35, 71–81.

Ridgway D, Wolff LJ (1993): Active immunization of children with leukemia and other malignancies. Leuk Lymphoma 9, 177–192.

Rieder J, Mischke R (2018): Immunosuppressive therapy in dogs and cats. Properties of drugs and their use in various immune-mediated diseases. Tierarztl Prax Ausg K Kleintiere Heimtiere 46, 105–188.

Riemer F, Kuehner KA, Ritz S, et al (2016): Clinical and laboratory features of cats with feline infectious peritonitis–a retrospective study of 231 confirmed cases (2000-2010). J Feline Med Surg 18, 348–356.

Rinkardt NE, Kruth SA, Kaushik A (1999): The effects of prednisone and azathioprine on circulating immunoglobulin levels and lymphocyte subpopulations in normal dogs. Can J Vet Res 63(1), 18-24.

Roberts ES, VanLare KA, Roycroft LM, et al (2015): Effect of high-dose ciclosporin on the immune response to primary and booster vaccination in immunocompetent cats. J Feline Med Surg 17, 101–109.

Robertson HD, Polk HC, Jr (1974): The mechanism of infection in patients with diabetes mellitus: A review of leukocyte malfunction. Surgery 75, 123–128.

Roth JA, Eilber FR, Morton DL (1978): Effect of adriamycin and high-dose methotrexate chemotherapy on in vivo and in vitro cell-mediated immunity in cancer patients. Cancer 41, 814–819.

Rubin LG, Levin MJ, Ljungman P, et al (2014): 2013 IDSA Clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58, 309–318.

Rytel MW, Dailey MP, Schiffman G, et al (1986): Pneumococcal vaccine immunization of patients with renal impairment. Proc Soc Exp Biol Med 182, 468–473.

Sabbioni ME, Castiglione M, Hurny C, et al (1999): Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients. Support Care Cancer 7, 149–153.

Salant H, Klainbart S, Kelmer E, Mazuz ML, Baneth G, Aroch I (2021): Systemic toxoplasmosis in a cat under cyclosporine therapy. Vet

Parasitol Reg Stud Rep 23, 100542.

Sánchez-Vizcaino F, Noble PJM, Jones PH, et al (2017): Demographics of dogs, cats, and rabbits attending veterinary practices in Great Britain as recorded in their electronic health records. BMC Vet Res 13, 218.

Sara E, Kotsakis A, Souklakos J, et al (1999): Post-chemotherapy lymphopoiesis in patients with solid tumors is characterized by CD4+ cell proliferation. Anticancer Res 19, 471–476.

Schaer M (2008): Immunocompromise in small animal medicine. The 33rd Congress of the World Small Animal Veterinary Association (WSAVA) *Abstract* 20.08.–24.08.2008; Dublin, Ireland.

Scherk M (2008): Vaccination and the Immune Status of the Cat. 33rd World Small Animal Veterinary Association (WSAVA) Congress, 20-08.-24.08.2008; Dublin, Irland.

Schultz RD, Thiel B, Mukhtar E, et al (2010): Age and long-term protective immunity in dogs and cats. J Comp Path 142, 102–108.

Schwebke J, Mujais S (1989): Vaccination in hemodialysis patients (editorial). Int J Artif Organs 12, 481–484.

Scott FW, Geissinger CM (1997): Duration of immunity in cats vaccinated with an inactivated feline panleukopenia, herpesvirus and calicivirus vaccine. Feline Practice 25, 12–19.

Scott FW, Geissinger CM (1999): Long-term immunity in cats vaccinated with an inactivated trivalent vaccine. Am J Vet Res 60, 652–658.

Sellon R, Hartmann K (2006): Feline immunodeficiency virus infection. In: Greene CE (ed.): Infectious Diseases of the Dog and Cat. 3rd ed. St. Louis, Missouri: Saunders: 131–142.

Serafini P, Borrello I, Bronte V (2006): Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16, 53-65.

Sikorski LE, Birkenheuer AJ, Holowaychuk MK, et al (2010): Babesiosis caused by a large *Babesia* species in 7 immunocompromised dogs. J Vet Intern Med 24, 127–131.

Simberkoff MS, Schiffman G, Katz LA, et al (1980): Pneumococcal capsular polysaccharide vaccination in adult chronic hemodialysis patients. J Lab Clin Med 96, 363–370.

Sonani B, Aslam F, Goyal A, Patel J, Bansal P (2021): COVID-19 vaccination in immunocompromised patients. Clin Rheumatol 40, 797–798.

Songaksorn N, Petsophonsakul W, Pringproa K, Lampang KN, Sthitmatee N, Sriphawattana N, Thongkorn K (2019): Production of polyclonal antibody against kidney antigens: A model for studying autoantibody in feline chronic kidney diseases. J Vet Sci 20, 73.

Songaksorn N, Petsophonsakul W, Pringproa K, Lampang KN, Sthitmatee N, Srifawattana N, Piyarungsri K, Thongkorn K (2021): Prevalence of autoantibodies that bind to kidney tissues in cats and association risk with antibodies to feline viral rhinotracheitis, calicivirus, and panleukopenia. J Vet Sci 22, 38.

Spada E, Perego R, Sgamma EA, Proverbio D (2018): Survival time and effect of selected predictor variables on survival in owned pet cats seropositive for feline immunodeficiency and leukemia virus attending a referral clinic in northern Italy. Prev Vet Med 150, 38–46.

Spano D, Zollo M (2012): Tumor microenvironment: A main actor in the metastasis process. Clin Exp Metastasis 29, 381–395.

Sykes JE, Ball LM, Bailiff NL, et al (2005): 'Candidatus *Mycoplasma haematoparvum*', a novel small haemotropic mycoplasma from a dog. Int J Syst Evol Microbiol 55, 27–30.

Taniguchi A, Ishida T, Konno T, et al (1990): Altered mitogen response of peripheral blood lymphocytes in different stages of feline immunodeficiency virus infection. JPN J Vet Sci 52, 513–518.

Taniguchi A, Ishida T, Washizu T, et al (1991): Humoral immune response to T cell dependent and independent antigens in cats infected with feline immunodeficiency virus. J Vet Med Sci 53, 333–335.

Ten Berge RJ, Schellekens PT, Hamerlynck JV, et al (1984): Combination chemotherapy and immune capacity in advanced ovarian carcinoma. Eur J Cancer Clin Oncol 20, 91-98.

Thiry E, Horzinek MC (2007): Vaccination guidelines: a bridge between official requirements and the daily use of vaccines. Rev Sci Tech 26, 511-517.

Tizard IR (2018a): B cells and their response to antigens. In: Tizard IR (ed.): Veterinary Immunology, 10th ed. St. Louis, Missouri, USA:

Elsevier: 147–161.

Tizard IR (2018b): Drugs and other agents that affect the immune system. In: Tizard IR (ed.): Veterinary Immunology, 10th ed. St. Louis, Missouri, USA: Elsevier: 463–470.

Uilenberg G, Franssen FF, Perié NM (1987): Relationships between *Cytauxzoon felis* and African piroplasmids. Vet Parasitol 26, 21–28.

Viviano KR (2022): Glucocorticoids, cyclosporine, azathioprine, chlorambucil, and mycophenolate in dogs and cats: Clinical uses, pharmacology, and side effects. Vet Clin N Am Small Anim Pract 52, 797–817.

Vogt AH, Rodan I, Brown M, et al (2010): AAFP-AAHA feline life stage guidelines. J Am Anim Hosp Assoc 46,70–85.

Walter CU, Biller BJ, Lana SE, et al (2006): Effects of chemotherapy on immune responses in dogs with cancer. J Vet Intern Med 20, 342–347.

Weiden PL, Storb R, Kolb HJ, et al (1974): Immune reactivity in dogs with spontaneous malignancy. J Natl Cancer Inst 53, 1049-1056.

Weinberger B, Grubeck-Loebenstein B (2012): Vaccines for the elderly. Clin Microbiol Infect 5, 100–108.

Whittemore JC, Hawley JR, Jensen WA, et al (2010): Antibodies against Crandell Rees feline kidney (CRFK) cell line antigens, alpha-enolase, and annexin A2 in vaccinated and CRFK hyperinoculated cats. *J Vet Intern Med* 24, 306–313.

Willett BJ, Hosie MJ, Dunsford TH, et al (1991): Productive infection of T-helper lymphocytes with feline immunodeficiency virus is accompanied by reduced expression of CD4. AIDS 5, 1469–1475.

Zignol M, Peracchi M, Tridello G, et al (2004): Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. Cancer 101, 635-641.